American Society of Retina Specialists

This episode of DocTalk features 5 expert retina specialists discussing the top line data from the conference.

Over 60% of patients in the second year of TENAYA and LUCERNE were on 16 week dosing in the faricimab group.

Machine learning algorithms successfully predicted visual and anatomic outcomes and dosing frequency in patients with macular edema secondary to CRVO.

Data show 77% of eyes with DME in the IRIS Registry received only one type of anti-VEGF agent over an average follow-up of 2.3 years.

The port delivery system provides good visual outcomes for patients with nAMD despite presence of fluid in post-hoc analysis of Archway trial.

A post-hoc analysis of the GATHER1 trial suggests avacincaptad pegol reduced GA lesion growth across all distances from the foveal center point, when compared to sham.

Longer time to intravitreal aflibercept injection (>3 months) showed less visual improvement versus shorter time (<1 month).

Dr. Singh discusses the promise of durability with the agent and the potential for reducing the amount of patient visits, while preserving visual outcomes.

More than 60% of faricimab patients could be treated every 4 months at 2-year mark of TENAYA and LUCERNE studies.

Overall 70% of the patients in both PDS with ranibizumab and ranibizumab alone had almost no retinal thickness fluctuations.

Real-world patients showed improvement in visual acuity and anatomic parameters, but are still at an early time point in TRUCKEE study.

Evidence of pegcetacoplan treatment effect observed in the distribution of patients across quartiles in both OAKS and DERBY.

Monthly or every other month intravitreal pegcetacoplan reported to be tolerated in DERBY and OAKS trials.

The best overall outcomes were attained in eyes without fluid and ellipsoid zone integrity preservation, investigators said.

An assessment of anti-VEGF dose regimen strategies concludes with little difference in outcomes among treatment arms at 2 years.

The retina field is equipped with ideal therapy and research informing implementation. Now it needs greater patient buy-in.

Assessment from a patient survey showed an association between increased rates of injection treatment and increased restriction on usual activity for patients.

Rishi P. Singh, MD, discusses new VISTA/VIVID data showing what really influences a patients' likelihood and time to DME resolution when treated with aflibercept.

Theodore Leng, MD, MS, defines the trends of patient discontinuation, and how direct caregivers may help to reduce risk of losing patients.

Arshad Khanani, MD, MA, explains how new measures made available to ophthalmology will help address a quickly growing patient population.

Veeral S. Sheth, MD, MBA, discusses what ophthalmologists will need to learn about PDS application for patients with AMD.

Theodore Leng, MD, MS, discusses new findings based on IRIS registry data showing long-term discontinuation trends in patients.

An approval may be pending for the unique delivery system. An expert explains its benefit for nAMD patients and physicians alike.

A retina care team highlighted positive patient feedback from their makeshift system; could it be a long-term solution?

A greater rate of intravitreal injection appointments were delayed last year, causing worse patient scores in BCVA and OTC.

New cohort analyses show endophthalmitis was not significantly reduced in treatment encounters where both physicians and patients were masked.

Findings from YOSEMITE and RHINE show a significant rate of patients on faricimab were able to extend their dosing to once every 16 weeks after a year of therapy.

Positive phase 1 and 2 findings support an ongoing efficacy assessment of the Ref-1 inhibitor for diabetic retinopathy and diabetic macular edema.

A new cross-sectional analysis from ASRS 2021 show White patients are generally overrepresented in randomized, controlled trials for DME.

Josh Mali, MD, of The Eyes Associates, joins HCPLive to review the key news and developments coming out of the American Society of Retina Specialists 2021 Scientific Meeting.